Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Ceftriaxone for the Treatment of Serious Infections

Ceftriaxone for the Treatment of Serious Infections Abstract • Ceftriaxone Is an investigational cephalosporin with a half-life of five to eight hours. In an uncontrolled study, we evaluated its efficacy and safety In 30 pediatric and 12 young adult patients with serious bacterial infections. This agent was administered to children at a dosage of 50 to 75 mg/kg/day intravenously in two divided doses. Those with CNS infections received 100 mg/kg/day. In adults, the dosage was 1 g either once or twice daily. The diseases we treated included pneumonia (17), sepsis (eight), ventriculoperitoneal shunt infections (three), osteomyelitis (three), brain abscess (two), peritonitis (two), and miscellaneous (seven). Clinical cures were achieved in all cases, although one child with cystic fibrosis and Pseudomonas pneumonia had persistent colonization in his sputum. No serious side effects were observed. Although not the agent of choice for many of these pathogens, ceftriaxone appears to represent an important alternative to therapy. (Am J Dis Child 1983;137:1044-1047) References 1. Eickhoff TC, Ehret J: Comparative in vitro studies of RO13-9904, a new cephalosporin derivative . Antimicrob Agents Chemother 1981;19: 435-442.Crossref 2. Steele RW, Eyre LB, Bradsher RW, et al: Pharmacokinetics of ceftriaxone in pediatric patients with meningitis . Antimicrob Agents Chemother 1983;23:191-194.Crossref 3. Bradsher RW: Ceftriaxone (RO 13-9904) therapy of serious infections . Antimicrob Agents Chemother 1982;22:36-42.Crossref 4. Steele RW, Bradsher RW: A comparison of ceftriaxone to standard therapy for bacterial meningitis. J Pediatr, in press. 5. Gnann JW Jr, Goetter WE, Elliott AM, et al: Ceftriaxone: In vitro studies and clinical evaluations . Antimicrob Agents Chemother 1982;22: 1-9.Crossref 6. Gavan TL, Barry AL: Microdilution test procedures , in Lennette EH, Balows A, Hausler WJ Jr, et al (eds): Manual for Clinical Microbiology . Washington, DC, American Society for Microbiology, 1980. 7. Patel IH, Chen S, Parsonnet M, et al: Pharmacokinetics of ceftriaxone in humans . Antimicrob Agents Chemother 1981;20:634-641.Crossref 8. Bennett JV, Brodie EJ, Benner EJ, et al: Simplified, accurate method for antibiotic assay of clinical specimens . Appl Microbiol 1966;14: 170-177. 9. Bradsher RW, Ulmer WC: β-Lactam antibiotic susceptibility of bacteria responsible for neonatal meningitis. Chemotherapy, in press. 10. Del Rio M, McCracken GH Jr, Nelson JD, et al: Pharmacokinetics and cerebrospinal fluid bactericidal activity of ceftriaxone in the treatment of pediatric patients with bacterial meningitis . Antimicrob Agents Chemother 1982;22: 622-627.Crossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Diseases of Children American Medical Association

Ceftriaxone for the Treatment of Serious Infections

Loading next page...
 
/lp/american-medical-association/ceftriaxone-for-the-treatment-of-serious-infections-f8GsHrrWwG

References (8)

Publisher
American Medical Association
Copyright
Copyright © 1983 American Medical Association. All Rights Reserved.
ISSN
0002-922X
DOI
10.1001/archpedi.1983.02140370006003
Publisher site
See Article on Publisher Site

Abstract

Abstract • Ceftriaxone Is an investigational cephalosporin with a half-life of five to eight hours. In an uncontrolled study, we evaluated its efficacy and safety In 30 pediatric and 12 young adult patients with serious bacterial infections. This agent was administered to children at a dosage of 50 to 75 mg/kg/day intravenously in two divided doses. Those with CNS infections received 100 mg/kg/day. In adults, the dosage was 1 g either once or twice daily. The diseases we treated included pneumonia (17), sepsis (eight), ventriculoperitoneal shunt infections (three), osteomyelitis (three), brain abscess (two), peritonitis (two), and miscellaneous (seven). Clinical cures were achieved in all cases, although one child with cystic fibrosis and Pseudomonas pneumonia had persistent colonization in his sputum. No serious side effects were observed. Although not the agent of choice for many of these pathogens, ceftriaxone appears to represent an important alternative to therapy. (Am J Dis Child 1983;137:1044-1047) References 1. Eickhoff TC, Ehret J: Comparative in vitro studies of RO13-9904, a new cephalosporin derivative . Antimicrob Agents Chemother 1981;19: 435-442.Crossref 2. Steele RW, Eyre LB, Bradsher RW, et al: Pharmacokinetics of ceftriaxone in pediatric patients with meningitis . Antimicrob Agents Chemother 1983;23:191-194.Crossref 3. Bradsher RW: Ceftriaxone (RO 13-9904) therapy of serious infections . Antimicrob Agents Chemother 1982;22:36-42.Crossref 4. Steele RW, Bradsher RW: A comparison of ceftriaxone to standard therapy for bacterial meningitis. J Pediatr, in press. 5. Gnann JW Jr, Goetter WE, Elliott AM, et al: Ceftriaxone: In vitro studies and clinical evaluations . Antimicrob Agents Chemother 1982;22: 1-9.Crossref 6. Gavan TL, Barry AL: Microdilution test procedures , in Lennette EH, Balows A, Hausler WJ Jr, et al (eds): Manual for Clinical Microbiology . Washington, DC, American Society for Microbiology, 1980. 7. Patel IH, Chen S, Parsonnet M, et al: Pharmacokinetics of ceftriaxone in humans . Antimicrob Agents Chemother 1981;20:634-641.Crossref 8. Bennett JV, Brodie EJ, Benner EJ, et al: Simplified, accurate method for antibiotic assay of clinical specimens . Appl Microbiol 1966;14: 170-177. 9. Bradsher RW, Ulmer WC: β-Lactam antibiotic susceptibility of bacteria responsible for neonatal meningitis. Chemotherapy, in press. 10. Del Rio M, McCracken GH Jr, Nelson JD, et al: Pharmacokinetics and cerebrospinal fluid bactericidal activity of ceftriaxone in the treatment of pediatric patients with bacterial meningitis . Antimicrob Agents Chemother 1982;22: 622-627.Crossref

Journal

American Journal of Diseases of ChildrenAmerican Medical Association

Published: Nov 1, 1983

There are no references for this article.